Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compared to $186.99 million a year, beating the consensus of $65.78 million. Product sales of $38 million for the third quarter of 2024 were primarily related to U.
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...
On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...
Drug maker Novavax Inc. (NVAX), while reporting narrower net loss in its third quarter, on Tuesday trimmed its fiscal 2024 forecast ...
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $8.91 which represents a decrease of $-0.27 or -2.94% from the prior close of $9.18. The stock opened at $9.25 and touched a low of ...
Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.
Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to ...
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback